Abstract | UNLABELLED: PATIENTS AND METHODS: RESULTS: About half patients ameliorated in agreement with both ACR 20 criteria and DAS28 evaluation. The clinical improvement was accompanied by a reduction of the steroid daily dosage. No relevant side effects were observed. CONCLUSION:
|
Authors | Paola Caramaschi, Sabrina Canestrini, Domenico Biasi, Antonio Carletto, Cinzia Scambi, Anna Scarperi, Lisa Maria Bambara |
Journal | Recenti progressi in medicina
(Recenti Prog Med)
Vol. 93
Issue 1
Pg. 19-24
(Jan 2002)
ISSN: 0034-1193 [Print] Italy |
Vernacular Title | Infliximab nell'artrite reumatoide aggressiva e refrattaria. Esperienza preliminare. |
PMID | 11850995
(Publication Type: Comparative Study, English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Antirheumatic Agents
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
- Infliximab
- Azathioprine
- Prednisone
- Methotrexate
|
Topics |
- Adult
- Aged
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Antirheumatic Agents
(administration & dosage, therapeutic use)
- Arthritis, Rheumatoid
(diagnosis, drug therapy)
- Azathioprine
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Infliximab
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Pilot Projects
- Prednisone
(therapeutic use)
- Time Factors
- Tumor Necrosis Factor-alpha
(immunology)
|